April 24th 2024
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Chronic-Phase CML: The OPTIC Study
Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.
Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.
Relapsed/Refractory CLL: Overview of the Treatment Landscape
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Liso-Cel Yields Encouraging Responses in Relapsed/Refractory CLL/SLL
June 7th 2023Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.